EICHOR
● Completed
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Condition: Carcinoma, Hepatocellular · Sponsor: Hoffmann-La Roche
About this study
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (134)
| Kaiser Permanente Los Angeles | Los Angeles, California, United States | — |
| Mercy Medical Center | Baltimore, Maryland, United States | — |
| Henry Ford Health System | Detroit, Michigan, United States | — |
| Columbia University Medical Center | New York, New York, United States | — |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | — |
| The University of Texas Southwestern Medical Center at Dallas | Dallas, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Swedish Cancer Inst. | Seattle, Washington, United States | — |
| St Vincent's Hospital Sydney | Darlinghurst, New South Wales, Australia | — |
| Lkh-Univ. Klinikum Graz | Graz, Austria | — |
| Klinikum Klagenfurt am Wörtersee | Klagenfurt, Austria | — |
| Medizinische Universität Wien | Vienna, Austria | — |
+ 122 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04102098